Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

UBS analyst Trung Huynh maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $31.00. The ...

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.72 which represents a decrease of $-0.74 or -2.69% from the prior close of $27.46. The stock opened at $27.11 and touched a low ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

On Thursday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $27.46 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.36. The stock opened at $27.53 and ...

Pfizer's newest anti-obesity program may disclose some of ... and it could easily constitute a catalyst for the stock price.

68.36% of the stock is owned by institutional investors and hedge funds. Several analysts recently commented on PFE shares. Wells Fargo & Company increased their target price on shares of Pfizer ...

But making Pfizer Inc an even more interesting and timely stock to look at, is the fact that in trading on Friday, shares of ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...